this author has yet to write their bio.
meanwhile lets just say that we are proud admin contributed a whooping 433 entries.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a marketing and distribution agreement with orion corporation (headquarters: espoo, finland; ceo: timo lappalainen, “orion”) concerning its parkinson’s disease treatments comtan®(entacapone) and stalevo®(levodopa/entacapone/carbidopa combination agent) in china.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito) announced today that, in association with its u.s. pharmaceutical subsidiary eisai inc. (collectively, “eisai”), it has reached an agreement with arena pharmaceuticals, inc. (headquarters: california, united states, president and ceo: amit d. munshi) to revise the november 2013 marketing and supply agreement it concluded with arena’s wholly owned subsidiary, arena pharmaceuticals gmbh (collectively, “arena”), for the chronic weight management treatment lorcaserin hydrochloride (generic name, u.s. brand name: belviq® / belviq xr®, “belviq”). under the new agreement, eisai acquires all of arena’s rights to develop and market belviq.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the anticancer agent treakisym® (generic name: bendamustine hydrochloride) has been approved in japan for an additional indication as first-line treatment for low-grade b-cell non-hodgkin′s lymphoma and mantle cell lymphoma (mcl). treakisym is the subject of a licensing agreement concluded between eisai and symbio pharmaceuticals limited (headquarters: tokyo, representative director, president & ceo: fuminori yoshida, “symbio”). through the approval of this additional indication, treakisym will now be available for adjunctive use with rituximab for untreated low-grade b-cell non-hodgkin′s lymphoma and mcl.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the results of an interim analysis of a phase ib/ii clinical study (study 218) of its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: halaven®, “eribulin”) in combination with the anti-pd-1 antibody pembrolizumab developed by merck & co., inc., kenilworth, nj, usa (known as msd outside the u.s. and canada), in patients with metastatic triple-negative breast cancer have been presented at the 39th annual san antonio breast cancer symposium held from december 6 to 10, 2016. development of this combination regimen is being conducted jointly under the cooperation of both companies.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has presented the latest two clinical trials (study 202 and study 006) data on its in-house discovered oral bace (beta amyloid cleaving enzyme ) inhibitor elenbecestat (development code: e2609) at the 9th clinical trials on alzheimer’s disease (ctad 2016) held from december 8 to 10 in san diego, the united states.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a series of abstracts highlighting the latest clinical data on its in-house developed halichondrin class microtubule dynamics inhibitor eribulin mesylate (product name: halaven®, “eribulin”) will be presented at the san antonio breast cancer symposium (sabcs2016) taking place in san antonio, the united states, from december 6 to 10.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the latest data on its antiepileptic drugs (aed) perampanel (product name: fycompa®) and rufinamide (product name: inovelon®, u.s. product name: banzel®) will be presented at the 70th american epilepsy society (aes) annual meeting to be held from december 2 to 6 in houston in the united states.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that eisai has been highly commended for its initiatives to promote access to medicines and ranked 11th among the world’s leading pharmaceutical companies in the access to medicine index (atm index) 2016.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its in-house developed anticancer agent halaven® (eribulin mesylate, “eribulin”) has been recommended by the u.k. national institute for health and clinical excellence (nice) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease (prior therapy may have included an anthracycline or a taxane, and capecitabine) in nice’s final appraisal determination (fad). eribulin is the first breast cancer treatment to be recommended by nice since 2007.
harvard business review has just announced the best-performing ceos in the world, in which ceo haruo naito was ranked 87th. among japanese companies, only three other ceos made the list, including nidec’s shigenobu nagamori (42nd), fast retailing’s tadashi yanai (46th) and softbank’s masayoshi son (73rd).
1066vip威尼斯 copyright(c) 2011 eisai china lnc.all rights reserved.
沪公网安备31010602001439号
021-62881220
本网站使用cookies以使您获得最佳的体验。为了继续浏览本网站，您需同意我们对cookies的使用。想要了解更多有关于cookies的信息，或不希望当您使用网站时出现cookies，请阅读我们的cookies声明！
we may request cookies to be set on your device. we use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
click on the different category headings to find out more. you can also change some of your preferences. note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
these cookies are strictly necessary to provide you with services available through our website and to use some of its features.
because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. you always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. but this will always prompt you to accept/refuse cookies when revisiting our site.
we fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. you are free to opt out any time or opt in for other cookies to get a better experience. if you refuse cookies we will remove all set cookies in our domain.
we provide you with a list of stored cookies on your computer in our domain so you can check what we stored. due to security reasons we are not able to show or modify cookies from other domains. you can check these in your browser security settings.
we also use different external services like google webfonts, google maps, and external video providers. since these providers may collect personal data like your ip address we allow you to block them here. please be aware that this might heavily reduce the functionality and appearance of our site. changes will take effect once you reload the page.
google webfont settings:
google map settings:
google recaptcha settings:
vimeo and youtube video embeds:
you can read about our cookies and privacy settings in detail on our privacy policy page.
privacy policy